Furthermore, short‐term intensive insulin therapy using continuous subcutaneous insulin infusion (CSII) can improve islet beta cell function in patients with newly diagnosed type 2 diabetes mellitus (T2DM), thus prolonging glycemic remission (Weng et al., 2008; Weng, 2017; Kramer, Zinman & Retnakaran, 2013). This evidence concerns the gene INS and type 2 diabetes mellitus.